Bicara Therapeutics (BCAX) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BCAX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bicara Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.63 |
| 52 Week High | US$30.99 |
| 52 Week Low | US$10.30 |
| Beta | 0 |
| 1 Month Change | -12.50% |
| 3 Month Change | 19.27% |
| 1 Year Change | 117.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.21% |
Recent News & Updates
Recent updates
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Summary Bicara Therapeutics is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization. Near-term catalysts are limited; major valuation inflection depends on mid-2027 interim data from the FORTIFI-HN01 phase 3 trial. Read the full article on Seeking Alpha
Phase III Progress In Head And Neck Cancer Will Reshape Long Term Outlook
Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company developing bifunctional antibodies for targeted tumor modulation, with a focus on its lead asset FICERA in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?
Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer
Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company focused on bifunctional antibodies for targeted tumor modulation, led by its FICERA program in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Bicara: Innovative Precision Tumor Targeting
Summary Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial health is robust, with $489.7 million in cash, ensuring operations through mid-2029, bolstered by a successful IPO and Series C funding. Early clinical data for ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows significant antitumor activity and manageable safety, supporting its potential market impact. Bicara's pivotal Phase 2/3 trial could establish ficerafusp alfa as a new standard of care, with a potential market revenue of $1.3 billion annually. Read the full article on Seeking AlphaWe Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me
Summary Bicara Therapeutics is a new biotech firm focusing on innovative cancer treatments, currently advancing its lead candidate, ficerafusp alfa, targeting challenging cancers like HNSCC. BCAX's financial health is strong, with sufficient capital to fund operations for about four years, but relies heavily on the success of ficerafusp alfa. Early trial results for ficerafusp alfa show promise, particularly in HPV-negative HNSCC, but the lack of diverse pipeline and early-stage data pose significant risks. Given the long wait for potential approval and high volatility, BCAX is a speculative investment better suited for patient, risk-tolerant investors, and I would personally watch for a favorable entry point. Read the full article on Seeking AlphaShareholder Returns
| BCAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | 4.9% | 0.09% |
| 1Y | 117.4% | 41.3% | 19.0% |
Return vs Industry: BCAX exceeded the US Biotechs industry which returned 41.3% over the past year.
Return vs Market: BCAX exceeded the US Market which returned 19% over the past year.
Price Volatility
| BCAX volatility | |
|---|---|
| BCAX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BCAX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 103 | Claire Mazumdar Clemon | www.bicara.com |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. Fundamentals Summary
| BCAX fundamental statistics | |
|---|---|
| Market cap | US$1.57b |
| Earnings (TTM) | -US$185.36m |
| Revenue (TTM) | n/a |
Is BCAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$185.36m |
| Earnings | -US$185.36m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/12 23:20 |
| End of Day Share Price | 2026/08/12 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bicara Therapeutics Inc. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Suranjit Mukherjee | BTIG |
| Eric Schmidt | Cantor Fitzgerald & Co. |